Mecobalamin
- Generic Name
- Mecobalamin
- Drug Type
- Small Molecule
- Chemical Formula
- C63H91CoN13O14P
- CAS Number
- 13422-55-4
- Unique Ingredient Identifier
- BR1SN1JS2W
- Background
Not Available
- Indication
Not Available
- Associated Conditions
- Vitamin B12 Deficiency
- Associated Therapies
- Nutritional supplementation
NPPA Sets Retail Prices for 84 Drugs Including Empagliflozin Combinations Following Patent Expiry
• India's National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 84 new drug formulations, including 36 combinations containing the recently off-patent diabetes medication empagliflozin.
• The price regulations follow the March 11, 2025 expiry of Boehringer Ingelheim's empagliflozin patent, opening the market to multiple pharmaceutical companies including Mankind Pharma, Lupin, and Alkem Laboratories.
• Beyond diabetes medications, the NPPA's pricing decisions also cover anti-hypertensive combinations containing telmisartan and metoprolol, as well as anti-inflammatory formulations with paracetamol and mefenamic acid.
HEALEY ALS Platform Trial: Streamlining Drug Development for Amyotrophic Lateral Sclerosis
• The HEALEY ALS Platform Trial is pioneering a new approach to accelerate the development of effective treatments for amyotrophic lateral sclerosis (ALS).
• By testing multiple drugs simultaneously using a shared infrastructure, the platform trial significantly reduces the time and cost associated with traditional clinical trials.
• Initial results from the platform have led to two drugs, CNM-Au8 and pridopidine, advancing to Phase 3 testing based on promising trends in secondary outcome measures and biomarker data.
• The collaborative effort unites patients, clinicians, scientists, and industry partners, fostering innovation and improving access to care across a network of over 70 sites.
New Drug Development Pipeline Shows Promise for ALS Treatment with 53 Candidates Under Investigation
• A comprehensive review of ALS drug development reveals 53 new drug candidates in clinical trials between 2020-2022, with 13 compounds advancing to Phase 3 trials and showing promising therapeutic potential.
• Five drugs demonstrated particularly strong efficacy: high-dose methylcobalamin, masitinib, AMX0035, CNM-Au8, and tofersen, with AMX0035 receiving FDA approval as the third treatment for ALS.
• The success of clinical trials is influenced by patient population homogeneity, observation duration, and analysis strategies, highlighting the importance of refined trial design in ALS drug development.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath